OralParenteralDosed ingredientTherapeutic flag
Acetazolamide
CAS 59-66-5
Acetazolamide (CAS 59-66-5) is a Phase 4 pharmaceutical compound with 27 bioactivity targets and 1,264 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
54
SOURCE
DrugCentral
Adverse signals
1,264
SOURCE
IUPHAR/BPS
PubMed IDs
7
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Acetazolamide
CAS Number
59-66-5
UNII
O3FX965V0I
InChIKey
BZKPWHYZMXOIDC-UHFFFAOYSA-N
ChEMBL ID
CHEMBL20
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Acetazolamide Sodium
black box warningdosed ingredientnatural productoralparenteraltherapeutic flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL20 | Small molecule
SOURCE
EMBL-EBI ChEMBL
54 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 666.8703831410826 nM | 2244 | - |
| - | IC50 | 2903.8812765957446 nM | 234 | - |
| - | Kd | 1682.0317821782178 nM | 101 | - |
| - | AC50 | 12587.944117647057 nM | 68 | - |
| - | MIC | 68.46052631578948 ug.mL-1 | 38 | - |
| - | Potency | 44407.43000000001 nM | 20 | - |
| - | Kd | 0.03666666666666667 /s | 6 | - |
| - | Ki | 0.48 Ratio | 1 | - |
| Carbonic anhydrase 2, isoform A; LD26647p Enzyme |
Ki | 7.11 | - | Drosophila melanogaster |
| Carbonic anhydrase 1; GH09688p Enzyme |
Ki | 6.97 | - | Drosophila melanogaster |
| Carbonic anhydrase 2 Enzyme |
Ki | 8.48 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 7.92 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 7.96 | - | Homo sapiens |
| Carbonic anhydrase 9 Enzyme |
Ki | 8.05 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 8.6 | - | Homo sapiens |
| Aquaporin-1 Transporter |
- | - | - | Homo sapiens |
| Carbonic anhydrase 5A, mitochondrial Enzyme |
Ki | 7.22 | - | Homo sapiens |
| Carbonic anhydrase 5B, mitochondrial Enzyme |
Ki | 7.27 | - | Homo sapiens |
| Carbonic anhydrase 7 Enzyme |
Ki | 8.6 | - | Homo sapiens |
| Carbonic anhydrase Enzyme |
Ki | 7.7 | - | Helicobacter pylori (strain ATCC 700392 / 26695) |
| Carbonic anhydrase 3 Enzyme |
Ki | 8.51 | - | Homo sapiens |
| Carbonic anhydrase 6 Enzyme |
Ki | 7.96 | - | Homo sapiens |
| Carbonic anhydrase 14 Enzyme |
Ki | 7.39 | - | Homo sapiens |
| Carbonic anhydrase 13 Enzyme |
Ki | 7.77 | - | Mus musculus |
| Carbonic anhydrase 4 Enzyme |
Ki | 7.15 | - | Bos taurus |
| Carbonic anhydrase 7 Enzyme |
Ki | 7.8 | - | Mus musculus |
| Carbonic anhydrase Enzyme |
Ki | 7.22 | - | Methanosarcina thermophila |
| Carbonic anhydrase Enzyme |
Ki | 4.92 | - | Methanothermobacter thermautotrophicus (strain ATCC 29096 / DSM 1053 / JCM 10044 / NBRC 100330 / Delta H) |
| Carbonic anhydrase 13 Enzyme |
Ki | 8.24 | - | Homo sapiens |
| Carbonic anhydrase 15 Enzyme |
Ki | 7.14 | - | Mus musculus |
| Carbonic anhydrase Enzyme |
Ki | 7.09 | - | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) |
| Carbonic anhydrase Enzyme |
Ki | 7.4 | - | Candida albicans (strain SC5314 / ATCC MYA-2876) |
| Probable transmembrane carbonic anhydrase (Carbonate dehydratase) (Carbonic dehydratase); Transmembrane carbonic anhydrase Enzyme |
Ki | 7.92 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Carbonic anhydrase Enzyme |
Ki | 7.96 | - | Candida glabrata (strain ATCC 2001 / CBS 138 / JCM 3761 / NBRC 0622 / NRRL Y-65) |
| Alpha carbonic anhydrase Enzyme |
Ki | 7.8 | - | Stylophora pistillata |
| Endochitinase Enzyme |
Ki | 4.68 | - | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) |
| Carbonic anhydrase Enzyme |
Ki | 7.13 | - | Stylophora pistillata |
| Carbonic anhydrase 2 Enzyme |
Ki | 8 | - | Cryptococcus neoformans var. grubii |
| Carbonic anhydrase Enzyme |
Ki | 5.24 | - | Dicentrarchus labrax |
| Astrosclerin-3 Enzyme |
Ki | 7.29 | - | Astrosclera willeyana |
| Beta-carbonic anhydrase 1 Enzyme |
Ki | 6.6 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Delta carbonic anhydrase Unclassified |
Ki | 7.08 | - | Thalassiosira weissflogii |
| Carbonic anhydrase 2 Enzyme |
Ki | 8.05 | - | Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) |
| Carbonic anhydrase 2 Enzyme |
IC50 | 6.02 | - | Bos taurus |
| Carbonic anhydrase Enzyme |
Ki | 9.1 | - | Homo sapiens |
| Carbonic anhydrase Enzyme |
IC50 | 7.8 | - | Bos taurus |
| Carbonic anhydrase V Enzyme |
Ki | 8.74 | - | Homo sapiens |
| Carbonic anhydrase Enzyme |
Ki | 7.57 | - | Flaveria bidentis |
| Carbonic anhydrase 3 Enzyme |
Ki | 4.08 | - | Bos taurus |
| Carbonic anhydrase Enzyme |
Ki | 7.56 | - | Anopheles gambiae |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Intraocular pressure increased | 96 | 292.189 | 10022806 |
| Metabolic acidosis | 166 | 278.47 | 10027417 |
| Angle closure glaucoma | 62 | 240.651 | 10002500 |
| Choroidal detachment | 43 | 215.551 | 10008783 |
| Idiopathic intracranial hypertension | 56 | 203.525 | 10078904 |
| Choroidal effusion | 37 | 181.759 | 10063970 |
| Hair follicle tumour benign | 29 | 147.92 | 10019043 |
| Papilloedema | 50 | 147.697 | 10033712 |
| Intracranial pressure increased | 45 | 114.691 | 10022773 |
| Off label use | 392 | 103.786 | 10053762 |
| Glaucoma | 56 | 98.896 | 10018304 |
| Toxic epidermal necrolysis | 63 | 84.712 | 10044223 |
| Corneal oedema | 25 | 76.599 | 10011033 |
| Drug ineffective | 416 | 71.616 | 10013709 |
| Hyphaema | 18 | 69.221 | 10020923 |
| Ocular surface disease | 13 | 68.789 | 10067103 |
| Hypercapnia | 30 | 63.949 | 10020591 |
| Retinal detachment | 31 | 60.863 | 10038848 |
| Congenital emphysema | 8 | 59.212 | 10010456 |
| Visual acuity reduced | 46 | 58.45 | 10047531 |
| Congenital intestinal malformation | 12 | 57.024 | 10061067 |
| Visual impairment | 76 | 55.234 | 10047571 |
| Drug ineffective for unapproved indication | 54 | 53.847 | 10051118 |
| Macular detachment | 11 | 51.962 | 10075873 |
| Hepatosplenic T-cell lymphoma | 14 | 48.708 | 10066957 |
| Complications of bone marrow transplant | 13 | 48.211 | 10010162 |
| Product contamination microbial | 13 | 45.525 | 10069175 |
| Drug reaction with eosinophilia and systemic symptoms | 51 | 44.384 | 10073508 |
| Foetal exposure during pregnancy | 67 | 44.131 | 10071404 |
| Iridocyclitis | 18 | 42.358 | 10022941 |
| Photophobia | 34 | 42.259 | 10034960 |
| Transmission of an infectious agent via product | 10 | 40.613 | 10072753 |
| Ophthalmic vein thrombosis | 9 | 39.247 | 10074349 |
| Intraocular pressure decreased | 9 | 38.57 | 10022804 |
| Burkholderia test positive | 12 | 38.499 | 10069960 |
| Flat anterior chamber of eye | 8 | 37.385 | 10016760 |
| Bacterial endophthalmitis | 8 | 37.13 | 10084936 |
| Vision blurred | 68 | 36.17 | 10047513 |
| Visual field defect | 21 | 35.204 | 10047555 |
| Endophthalmitis | 19 | 34.574 | 10014801 |
| Acute generalised exanthematous pustulosis | 25 | 34.56 | 10048799 |
| Acidosis | 27 | 34.04 | 10000486 |
| Crystalluria | 10 | 33.299 | 10011509 |
| Corneal opacity | 11 | 32.529 | 10011035 |
| Non-cardiogenic pulmonary oedema | 11 | 32.356 | 10029538 |
| Cataract | 49 | 31.784 | 10007739 |
| Somatostatin receptor scan abnormal | 5 | 31.375 | 10062140 |
| Hypotony of eye | 8 | 31.094 | 10021124 |
| Cerebral venous sinus thrombosis | 12 | 29.683 | 10083037 |
| Acidosis hyperchloraemic | 9 | 29.189 | 10000489 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
6 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| carbonic anhydrase 7 CA7 |
Inhibition | 8.600000381469727 pKi | 20605094 |
| carbonic anhydrase 1 CA1 |
Inhibition | 6.599999904632568 pKi | 15546717|15686894|20605094 |
| carbonic anhydrase 12 CA12 |
Inhibition | 8.239999771118164 pKi | 15686894|20605094 |
| carbonic anhydrase 13 Car13 |
Inhibition | 7.769999980926514 pKi | 20605094 |
| carbonic anhydrase 14 CA14 |
Inhibition | 7.389999866485596 pKi | 15454239|20605094 |
| carbonic anhydrase 4 CA4 |
Inhibition | 7.130000114440918 pKi | 15603956|20605094 |
SOURCE
PharmGKB
2 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
HLA-B (PA35056) HLA-B*59:01:01:01
HLA-B *59:01:01:01 is associated with risk of Stevens-Johnson Syndrome when treated with acetazolamide.
Evidence: -; PMID 21342230
HLA-B HLA-B*59:01
Stevens-Johnson Syndrome
Evidence: 3; PMID 1
SOURCE
NLM RxNorm
10 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| Acetazolamide | 167 | SU | MTHSPL |
| ACETAZOLAMIDE | 167 | SU | MTHSPL |
| acetazolamide | 167 | SU | MTHSPL |
| Acetazolamide Sodium | 91406 | SU | MTHSPL |
| ACETAZOLAMIDE SODIUM | 91406 | SU | MTHSPL |
| acetazolamide sodium | 91406 | SU | MTHSPL |
| acetazolamide | 167 | IN | RXNORM |
| acetaZOLAMIDE | 167 | TMSY | RXNORM |
| acetazolamide sodium | 91406 | PIN | RXNORM |
| acetaZOLAMIDE sodium | 91406 | TMSY | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Agitation | acetazolamide | PT | C0085631 |
| Agranulocytosis | acetazolamide | LLT | C0001824 |
| Agranulocytosis | acetazolamide | PT | C0001824 |
| Anaphylactic shock | acetazolamide | LLT | C0002792 |
| Anaphylactic shock | acetazolamide | PT | C0002792 |
| Anaphylactic shock | acetazolamide | PT | C0002792 |
| Anaphylactoid reaction | acetazolamide | LLT | C0340865 |
| Anaphylactoid reaction | acetazolamide | PT | C0340865 |
| Aplastic anaemia | acetazolamide | LLT | C0002874 |
| Aplastic anaemia | acetazolamide | PT | C0002874 |
| Appetite absent | acetazolamide | LLT | C1971624 |
| Asthenia | acetazolamide | PT | C0004093 |
| Ataxia | acetazolamide | LLT | C0004134 |
| Ataxia | acetazolamide | PT | C0004134 |
| Blood disorder | acetazolamide | LLT | C0018939 |
| Blood disorder | acetazolamide | PT | C0018939 |
| Body temperature increased | acetazolamide | LLT | C0015967 |
| Body temperature increased | acetazolamide | PT | C0015967 |
| Confusional state | acetazolamide | LLT | C0009676 |
| Confusional state | acetazolamide | PT | C0009676 |
| Convulsion | acetazolamide | LLT | C0036572 |
| Convulsion | acetazolamide | PT | C0036572 |
| Decreased appetite | acetazolamide | PT | C0232462 |
| Diarrhoea | acetazolamide | LLT | C0011991 |
| Diarrhoea | acetazolamide | PT | C0011991 |
| Digestion impaired | acetazolamide | LLT | C0232459 |
| Discomfort | acetazolamide | PT | C0234215 |
| Dizziness | acetazolamide | LLT | C0012833 |
| Dizziness | acetazolamide | PT | C0012833 |
| Drowsiness | acetazolamide | LLT | C0013144 |
| Dysgeusia | acetazolamide | LLT | C0013378 |
| Dysgeusia | acetazolamide | PT | C0013378 |
| Dyspepsia | acetazolamide | PT | C0013395 |
| Electrolyte imbalance | acetazolamide | LLT | C0342579 |
| Electrolyte imbalance | acetazolamide | PT | C0342579 |
| Erythema multiforme | acetazolamide | PT | C0014742 |
| Excitement | acetazolamide | LLT | C0233571 |
| Fatigue | acetazolamide | LLT | C0015672 |
| Fatigue | acetazolamide | PT | C0015672 |
| Feeling abnormal | acetazolamide | PT | C1443060 |
| Feeling abnormal | acetazolamide | PT | C1443060 |
| Flushing | acetazolamide | LLT | C0016382 |
| Flushing | acetazolamide | PT | C0016382 |
| Gastrointestinal disorder | acetazolamide | PT | C0017178 |
| Gastrointestinal disorder | acetazolamide | PT | C0017178 |
| Glycosuria | acetazolamide | LLT | C0017979 |
| Glycosuria | acetazolamide | PT | C0017979 |
| Growth retardation | acetazolamide | LLT | C0151686 |
| Growth retardation | acetazolamide | PT | C0151686 |
| Haematuria | acetazolamide | LLT | C0018965 |
| Haematuria | acetazolamide | PT | C0018965 |
| Headache | acetazolamide | LLT | C0018681 |
| Headache | acetazolamide | PT | C0018681 |
| Hepatic failure | acetazolamide | PT | C0085605 |
| Hepatic function abnormal | acetazolamide | LLT | C0086565 |
| Hepatic function abnormal | acetazolamide | PT | C0086565 |
| Hepatic insufficiency | acetazolamide | LLT | C1306571 |
| Hepatic necrosis | acetazolamide | LLT | C0151798 |
| Hepatic necrosis | acetazolamide | PT | C0151798 |
| Hepatobiliary disease | acetazolamide | LLT | C0267792 |
| Hepatobiliary disease | acetazolamide | PT | C0267792 |
| Hypoaesthesia | acetazolamide | PT | C0020580 |
| Hypoglycaemia | acetazolamide | LLT | C0020615 |
| Hypoglycaemia | acetazolamide | PT | C0020615 |
| Hypokalaemia | acetazolamide | LLT | C0020621 |
| Hypokalaemia | acetazolamide | PT | C0020621 |
| Hyponatraemia | acetazolamide | LLT | C0020625 |
| Hyponatraemia | acetazolamide | PT | C0020625 |
| Ill-defined disorder | acetazolamide | PT | C2047937 |
| Injection site pain | acetazolamide | LLT | C0151828 |
| Injection site pain | acetazolamide | PT | C0151828 |
| Irritability | acetazolamide | LLT | C0022107 |
| Irritability | acetazolamide | PT | C0022107 |
| Jaundice cholestatic | acetazolamide | LLT | C0022354 |
| Jaundice cholestatic | acetazolamide | PT | C0022354 |
| Leukopenia | acetazolamide | LLT | C0023530 |
| Leukopenia | acetazolamide | PT | C0023530 |
| Malaise | acetazolamide | LLT | C0231218 |
| Malaise | acetazolamide | PT | C0231218 |
| Melaena | acetazolamide | LLT | C0025222 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acetazolamide used for in pharmaceutical contexts?
Acetazolamide (CAS 59-66-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acetazolamide?
Acetazolamide has 1,264 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Intraocular pressure increased, Metabolic acidosis, Angle closure glaucoma, Choroidal detachment, Idiopathic intracranial hypertension. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acetazolamide also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Acetazolamide.
What clinical phase is Acetazolamide in?
Acetazolamide is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Acetazolamide?
Acetazolamide has 54 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, isoform A; LD26647p, Carbonic anhydrase 1; GH09688p, Carbonic anhydrase 2, Carbonic anhydrase 1, Carbonic anhydrase 4.